Francesca Stillitano

Small molecule-mediated directed differentiation of human embryonic stem cells toward ventricular cardiomyocytes.

Considerations for pre-clinical models and clinical trials of pluripotent stem cell-derived cardiomyocytes.

Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy.

Genomic correction of familial cardiomyopathy in human engineered cardiac tissues.

Gene Transfer in Cardiomyocytes Derived from ES and iPS Cells.

Modeling susceptibility to drug-induced long QT with a panel of subject-specific induced pluripotent stem cells.

Functional Human Beige Adipocytes From Induced Pluripotent Stem Cells.

Exosomal microRNA-21-5p Mediates Mesenchymal Stem Cell Paracrine Effects on Human Cardiac Tissue Contractility.

Functional and transcriptomic insights into pathogenesis of R9C phospholamban mutation using human induced pluripotent stem cell-derived cardiomyocytes.

Cardiac Tissue Engineering Models of Inherited and Acquired Cardiomyopathies.

Adult human cardiac stem cell supplementation effectively increases contractile function and maturation in human engineered cardiac tissues.

Impaired Right Ventricular Calcium Cycling Is an Early Risk Factor in R14del-Phospholamban Arrhythmias.

Generation of human induced pluripotent stem cell (iPSC) lines derived from five patients carrying the pathogenic phospholamban-R14del (PLN-R14del) variant and three non-carrier family members.

Isoform changes of action potential regulators in the ventricles of arrhythmogenic phospholamban-R14del humanized mouse hearts.

Myofilament Alterations Associated with Human R14del-Phospholamban Cardiomyopathy.